FogPharma vs Tempus

Side-by-side comparison of AI visibility scores, market position, and capabilities

Tempus leads in AI visibility (74 vs 34)
FogPharma logo

FogPharma

EmergingLife Sciences & BioTech

Cell-Penetrating Peptide Cancer Therapeutics

FogPharma develops cell-penetrating mini-proteins (CPMPs) to target intracellular cancer drivers like beta-catenin and FOXM1 that are undruggable by antibodies; raised $174M including a $100M Series C in 2023;

AI VisibilityBeta
Overall Score
D34
Category Rank
#189 of 198
AI Consensus
74%
Trend
stable
Per Platform
ChatGPT
28
Perplexity
34
Gemini
34

About

FogPharma is a clinical-stage biopharmaceutical company founded in 2015 by Gregory Verdine and headquartered in Cambridge, Massachusetts, developing a novel class of cancer therapeutics based on cell-penetrating mini-proteins (CPMPs). Traditional cancer drugs fall into two broad categories: small molecules that can penetrate cells but struggle to bind complex protein surfaces, and antibodies that bind complex surfaces with high specificity but cannot enter cells. FogPharma's CPMPs are designed to do both — penetrate cell membranes and engage large, complex intracellular protein targets that cause cancer but have historically been considered undruggable.

Full profile
Tempus logo

Tempus

LeaderLife Sciences & BioTech

AI-Enabled Precision Medicine

Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.

AI VisibilityBeta
Overall Score
B74
Category Rank
#11 of 198
AI Consensus
68%
Trend
stable
Per Platform
ChatGPT
71
Perplexity
68
Gemini
80

About

Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.

Full profile

AI Visibility Head-to-Head

34
Overall Score
74
#189
Category Rank
#11
74
AI Consensus
68
stable
Trend
stable
28
ChatGPT
71
34
Perplexity
68
34
Gemini
80
30
Claude
77
39
Grok
69

Key Details

Category
Cell-Penetrating Peptide Cancer Therapeutics
AI-Enabled Precision Medicine
Tier
Emerging
Leader
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.